Craft

Seagen

Revenue

$2 B

FY, 2022

Seagen Summary

Company Summary

Overview
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Its products include ADCETRIS, for the treatment of classical Hodgkin lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and other CD30-expressing peripheral T-cell lymphomas (PTCL); PADCEV, indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC); TUKYSA for the treatment of adult patients with advanced unrespectable or metastatic HER2-positive breast cancer, including patients with brain metastases; and TIVDAK for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The company also specializes in antibody-drug conjugate (ADC) and sugar-engineered antibody (SEA) technologies.
Type
Subsidiary
Status
Active
Founded
1998
HQ
Bothell, WA, US | view all locations
Website
https://www.seagen.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • David R. Epstein

    David R. Epstein, Chief Executive Officer and Director

  • Todd Simpson

    Todd Simpson, Chief Financial Officer

    • Vaughn Himes

      Vaughn Himes, Chief Technical Officer

    • Peggy Pinkston

      Peggy Pinkston, Chief Human Resources Officer

      Operating MetricsView all

      Product Categories

      4

      Q3, 2023

      Facilities Leased

      11

      FY, 2022

      Facility Space Leased, sq. ft.

      258K

      Q3, 2023

      LocationsView all

      11 locations detected

      • Bothell, WA HQ

        United States

        21717 30th Drive S.E., Building 3

      • Bothell, WA

        United States

        21823 30th Drive S.E.

      • Mississauga, ON

        Canada

        2000 Argentia Road Plaza 3, Suite 400

      • Hørsholm

        Denmark

        Agern Alle 24

      • Rueil-Malmaison, IDF

        France

        55 Av. de Colmar

      • München, BY

        Germany

        Maximilianstr. 13, 3rd floor

      and 5 others

      Seagen Financials

      Summary Financials

      Revenue (Q3, 2023)
      $648.7M
      Gross profit (Q3, 2023)
      $483.4M
      Net income (Q3, 2023)
      ($215.8M)
      Cash (Q3, 2023)
      $428.6M
      EBIT (Q3, 2023)
      ($231.3M)

      Footer menu